Project description
An innovative platform for faster, safer and cost-efficient drug discovery
There is an ongoing medical need for antimicrobial drugs that target viruses or antibiotic-resistant bacteria. The EU-funded SIGNIA project has developed a novel platform for screening pharmaceutical compounds with antimicrobial activity faster and more efficiently. The novelty underlying the SIGNIA approach is that drug discovery and selection are based on the efficient targeting of cellular rather than pathogenic determinants. This avoids the selective pressure put on microbes by traditional drugs, which may lead to mutation and resistance. Moreover, it has the potential to identify drugs with a broad-spectrum antimicrobial activity.
Objective
The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens. This phenomenon is outpacing the industry’s capacity for drug discovery and development. Antimicrobial resistance is costing the EU today €1.5 billion and 25,000 deaths annually. Developing de novo classical drugs is very costly and time consuming, and for every new drug released a resistant strain has rapidly emerged. This paradigm is hindering our ability to respond to outbreaks. Among causative organisms, viruses pose a major threat, being responsible for the outbreaks impacting the world in the past decade (SARS, Influenza A, MERS, etc). Although some antivirals have been developed for them, they lose their efficacy rapidly due to the high mutation rate of viruses, which alters the antigenic features originally used to develop the drug. Thus, there is an urgent need for novel discovery methods that allow to accelerate the development of broad-spectrum and mutability-independent antimicrobials. In response, Signia Therapeutics has developed and validated a drug discovery platform for fast identification of compounds with antimicrobial activity. Instead of selecting drugs that target pathogen determinants, it selects drugs that target determinants of the infected cell. This method offers key advantages: i) avoids the impact of microbe intrinsic mutability; ii) broad spectrum drugs can be identified. Since the platform seeks for antimicrobial applications among drugs already commercialized (repurposing) and among pharma libraries (recycling), drug discovery becomes faster, safer and cost-efficient. Having reached the functional stage (TRL6), this project encloses the roadmap to finalise the platform’s development and its preparation for market. Once completed, this project will have huge impacts for society (better management of infections and preparedness against outbreaks), and for our company (expected ROI of €2.1 from this project after 5 years).
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- social scienceseconomics and businesseconomicshealth economicseconomic impact of epidemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
69100 Villeurbanne
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.